Design of a phase 2b randomized clinical trial (ENDEAVOR) to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in HF with preserved and mildly reduced EF
20 May 2023 (08:00 - 20:00)
Organised by: 
About the speaker
Karolinska University Hospital, Stockholm (Sweden)
2 More presentations in this session
Doctor M. Kim (Seoul, KR)
Access the full session
The Event
Heart Failure 2023
20 May - 23 May 2023
You may be interested in
Congress Session
Congress Presentation
